Table 8A.9.2: Demographic Descriptive Statistics by Soft Tissue Cancer Type, by Age, United States, 1998-2011

Malignant Tumor, spindlice of lyner-Sarcoma, NoS. Spindle cell byner-Sarcoma; 13979 833 (6.0%) 1043 (7.5%) 1734 (12.4%) 2457 (17.6%) 2592 (18.5%) 2874 (20.6%) 2477 (17.5%) 2502 (18.5%) 2874 (20.6%) 2477 (17.5%) 2502 (18.5%) 2874 (20.6%) 2477 (17.5%) 2502 (18.5%) 2874 (20.6%) 2477 (17.5%) 2502 (18.5%) 2874 (20.6%) 2477 (17.5%) 2502 (18.5%) 2470 (19.5%			Age Category (N (% in Age Group))						
NOS. Spindle cell surcoma, Undifferentiated arroama, NOS surcoma, Stromal stromant acroma, NOS responsible control of the strong strong strong acromal strong and strong s	<u>Туре</u>	Total N	<u>18-29</u>	<u>30-39</u>	<u>40-49</u>	<u>50-59</u>	<u>60-69</u>	<u>70-79</u>	<u>80+</u>
sarcoma, Stromal sarcoma, NOS	Malignant Tumor, spindle cell type; Sarcoma,								
Fibrous Nistlocytoms, melignant 1328 281 (2.178) 5.99 (14.48) 131 (2.98) 2136 (15.18) 6.040 (19.99) 3379 (25.48) 2935 (12.22 10posarcoma Myxod 4304 62 (1.48) 1874 (4.48) 602 (14.89)	NOS; Spindle cell sarcoma; Undifferentiated	13979	833 (6.0%)	1043 (7.5%)	1733 (12.4%)	2457 (17.6%)	2592 (18.5%)	2874 (20.6%)	2447 (17.5%)
Liposarcoma Myrolid	sarcoma; Stromal sarcoma, NOS								
Liposarcoma, well differentiated 4304 62 (1.4%) 187 (4.3%) 604 (14%) 933 (22.1%) 1081 (25.1%) 913 (21.2%) 504 (11.7%) 507 (13.7%) 507	Fibrous histiocytoma, malignant	13289	281 (2.1%)	590 (4.4%)	1312 (9.9%)	2136 (16.1%)	2640 (19.9%)	3379 (25.4%)	2951 (22.2%)
Symovial sarcoma (NOS, spindle cell epithelioid cell epithelioid (alt 112 (26.6%)	Liposarcoma Myxoid	4349	381 (8.8%)	810 (18.6%)	1082 (24.9%)	856 (19.7%)	579 (13.3%)	409 (9.4%)	232 (5.3%)
Sear Common Sear	Liposarcoma, well differentiated	4304	62 (1.4%)	187 (4.3%)	604 (14%)	953 (22.1%)	1081 (25.1%)	913 (21.2%)	504 (11.7%)
Maignant peripheral nerve sheath tumor; Neurilemmona, malignant; MPNST with 367 691 (18.1%) 680 (17.8%) 723 (18.9%) 646 (16.9%) 471 (12.3%) 376 (9.8%) 240 (6.3%) 724 (18.9%) 723 (18.9%)		4175	1112 (26.6%)	877 (21%)	904 (21.7%)	620 (14.9%)	358 (8.6%)	207 (5.0%)	97 (2.3%)
Neurlienmoma, malignant; MPNST with mathor m	Giant cell sarcoma	4141	89 (2.1%)	189 (4.6%)	413 (10%)	810 (19.6%)	919 (22.2%)	945 (22.8%)	776 (18.7%)
Demarcoma, NOS 2876 48 (1.7%) 163 (5.7%) 380 (13.2%) 604 (21%) 639 (22.2%) 641 (22.3%) 401 (13.97)	Neurilemmoma, malignant; MPNST with	3827	691 (18.1%)	680 (17.8%)	723 (18.9%)	646 (16.9%)	471 (12.3%)	376 (9.8%)	240 (6.3%)
Dermatofibrosarcoma, NOS; Pigmented dermatofibrosarcoma protuberans	Hemangiosarcoma	3471	92 (2.7%)	138 (4.0%)	261 (7.5%)	472 (13.6%)	684 (19.7%)	932 (26.9%)	892 (25.7%)
Fibroarrooma protuberans	Liposarcoma, NOS	2876	48 (1.7%)	163 (5.7%)	380 (13.2%)	604 (21%)	639 (22.2%)	641 (22.3%)	401 (13.9%)
Fibrosarcoma NOS 2102 202 (9.6%) 264 (12.6%) 366 (17.4%) 374 (17.8%) 314 (14.9%) 352 (16.7%) 230 (10.9%) 210 (10.9%) 247 (2.7%) 180 (10.2%) 342 (19.3%) 452 (25.6%) 428 (24.3%) 302 (17.18) 210 (10.9%) 247 (2.7%) 248 (10.9%) 342 (19.3%) 452 (25.6%) 428 (24.3%) 302 (17.18) 248 (25.6%) 248 (2776	459 (16.5%)	684 (24.6%)	693 (25%)	515 (18.6%)	221 (8.0%)	147 (5.3%)	57 (2.1%)
Liposarcoma Dedifferentiated 1768 16 (0.9%) 47 (2.7%) 180 (10.2%) 342 (19.3%) 452 (25.6%) 429 (24.3%) 302 (17.19 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Fibromyxosarcoma	2356	204 (6.1%)	289 (8.6%)	459 (13.7%)	642 (19.1%)	664 (19.8%)	593 (17.7%)	505 (15%)
Epinosarcoma Pleomorphic 1711 33 (1.9%) 71 (4.1%) 179 (10.5%) 342 (20%) 403 (23.6%) 428 (25%) 255 (14.9%) Ewing sarcoma; Peripheral neuroectodermal tumor; Askin tumor; Primitive neuroectodermal 1496 666 (44.5%) 309 (20.7%) 242 (16.2%) 141 (19.4%) 70 (4.7%) 49 (3.3%) 19 (1.3%) 19 (1.3%) 19 (1.5%) 141 (19.4%)	Fibrosarcoma, NOS	2102	202 (9.6%)	264 (12.6%)	366 (17.4%)	374 (17.8%)	314 (14.9%)	352 (16.7%)	230 (10.9%)
Ewing sarcoma; Peripheral neuroectodermal tumor; Askin tumor; Primitive neuroectodermal tumor; Askin tumor; Primitive neuroectodermal tumor 1496 666 (44.5%) 309 (20.7%) 242 (16.2%) 141 (9.4%) 70 (4.7%) 49 (3.3%) 19 (1.3%) pithelioid sarcoma 1155 241 (20.9%) 198 (17.1%) 207 (17.9%) 195 (16.9%) 124 (10.7%) 115 (10%) 75 (6.5%) Chondrosarcoma Myxoid 854 34 (4.0%) 93 (10.9%) 165 (19.3%) 200 (23.4%) 186 (21.8%) 114 (13.3%) 62 (7.3%) Chondrosarcoma, NOS 581 41 (7.1%) 70 (12.0%) 82 (14.1%) 121 (20.8%) 108 (18.6%) 113 (19.4%) 46 (7.9%) Hemangiopericytoma, malignant 566 27 (4.8%) 70 (12.4%) 100 (17.7%) 132 (23.3%) 112 (19.8%) 88 (15.5%) 37 (6.5%) Pleemorphic rhabdomyosarcoma, adult type 562 49 (8.7%) 42 (7.5%) 75 (13.3%) 122 (21.7%) 112 (19.9%) 98 (17.4%) 66 (11.4%) Osteosarcoma, NOS; Chondroblastic 562 49 (8.7%) 42 (7.5%) 75 (13.3%) 105 (18.8%) 109 (19.5%) 99 (17.4%) </td <td>Liposarcoma Dedifferentiated</td> <td>1768</td> <td>16 (0.9%)</td> <td>47 (2.7%)</td> <td>180 (10.2%)</td> <td>342 (19.3%)</td> <td>452 (25.6%)</td> <td>429 (24.3%)</td> <td>302 (17.1%)</td>	Liposarcoma Dedifferentiated	1768	16 (0.9%)	47 (2.7%)	180 (10.2%)	342 (19.3%)	452 (25.6%)	429 (24.3%)	302 (17.1%)
tumor; Askin tumor; Primitive neuroectodermal 1496 666 (44.5%) 309 (20.7%) 242 (16.2%) 141 (9.4%) 70 (4.7%) 49 (3.3%) 19 (1.3% tumor septimental	Liposarcoma Pleomorphic	1711	33 (1.9%)	71 (4.1%)	179 (10.5%)	342 (20%)	403 (23.6%)	428 (25%)	255 (14.9%)
Epithelioid sarcoma 1155 241 (20.9%) 198 (17.1%) 207 (17.9%) 195 (16.9%) 124 (10.7%) 115 (10%) 75 (6.5%) Chondrosarcoma Myxoid 854 34 (4.0%) 93 (10.9%) 165 (19.3%) 200 (23.4%) 186 (21.8%) 114 (13.3%) 62 (7.3% (14.1%) 70 (12.0%) 82 (14.1%) 121 (20.8%) 108 (18.6%) 113 (19.4%) 46 (7.9% (14.1%) 109 (17.1%) 132 (23.3%) 112 (19.8%) 88 (15.5%) 37 (6.5% (14.1%) 109 (17.1%) 132 (23.3%) 112 (19.8%) 88 (15.5%) 37 (6.5% (14.1%) 109 (17.1%) 132 (23.3%) 112 (19.8%) 88 (15.5%) 37 (6.5% (14.1%) 109 (17.1%) 132 (23.3%) 112 (19.8%) 88 (15.5%) 37 (6.5% (14.1%) 109 (17.1%) 132 (23.3%) 112 (19.8%) 134 (23.7%) 111 (19.6%) 185 (15.5%) 100 (18.3%) 100 (17.8%) 134 (23.7%) 111 (19.8%) 186 (11.4%) 114 (13.3%	Ewing sarcoma; Peripheral neuroectodermal								
Chondrosarcoma Myxoid 854 34 (4.0%) 93 (10.9%) 165 (19.3%) 200 (23.4%) 186 (21.8%) 114 (13.3%) 62 (7.3%) Chondrosarcoma, NOS 581 41 (7.1%) 70 (12.0%) 82 (14.1%) 121 (20.8%) 108 (18.6%) 113 (19.4%) 46 (7.9%) Hemangiopericytoma, malignant 566 27 (4.8%) 70 (12.4%) 100 (17.7%) 132 (23.3%) 112 (19.8%) 88 (15.5%) 37 (6.5%) Pleomorphic rhabdomyosarcoma, adult type 566 24 (4.2%) 38 (6.7%) 69 (12.2%) 102 (18%) 134 (23.7%) 111 (19.6%) 88 (15.5%) 37 (6.5%) Osteosarcoma, NOS; Chondroblastic osteosarcoma 562 49 (8.7%) 42 (7.5%) 75 (13.3%) 122 (21.7%) 112 (19.9%) 98 (17.4%) 64 (11.4%) osteosarcoma; Fibroblastic osteosarcoma 558 14 (2.5%) 36 (6.5%) 88 (15.8%) 105 (18.8%) 109 (19.5%) 109 (19.5%) 97 (17.4%) Rhabdomyosarcoma, NOS (555 130 (23.4%) 65 (11.7%) 51 (9.2%) 89 (16.0%) 80 (14.4%) 86 (15.5%) 54 (9.7%) 110 (21.8%) 113 (20.5%) 120 (21.8%) 99 (18.0%) 79 (14.4%) 45 (8.2%) 110 (21.4%) 111 (20.5%) 105 (19.4%) 89 (16.0%) 80 (14.4%) 45 (8.2%) 110 (21.4%) 111 (20.5%) 105 (19.4%) 44 (8.1%) 26 (4.8%) 105 (19.4%) 44 (8.1%) 26 (4.8%) 105 (19.4%) 44 (8.1%) 26 (4.8%) 105 (19.4%) 44 (8.1%) 26 (4.8%) 105 (19.4%) 45 (8.2%) 105 (19.4%) 44 (8.1%) 26 (4.8%) 105 (19.4%) 45 (8.2%) 105 (19.4%) 45 (8.2%) 105 (19.4%) 105 (1496	666 (44.5%)	309 (20.7%)	242 (16.2%)	141 (9.4%)	70 (4.7%)	49 (3.3%)	19 (1.3%)
Chondrosarcoma, NOS 581 41 (7.1%) 70 (12.0%) 82 (14.1%) 122 (20.8%) 108 (18.6%) 113 (19.4%) 46 (7.9%) Hemangiopericytoma, malignant 566 27 (4.8%) 70 (12.4%) 100 (17.7%) 132 (23.3%) 112 (19.8%) 88 (15.5%) 37 (6.5%) Pleomorphic rhabdomyosarcoma, adult type 566 24 (4.2%) 38 (6.7%) 69 (12.2%) 102 (18%) 134 (23.7%) 111 (19.6%) 88 (15.5%) 37 (6.5%) Osteosarcoma, NOS; Chondroblastic osteosarcoma 562 49 (8.7%) 42 (7.5%) 75 (13.3%) 122 (21.7%) 112 (19.9%) 98 (17.4%) 64 (11.4%) Myxosarcoma spibroblastic osteosarcoma 558 14 (2.5%) 36 (6.5%) 88 (15.8%) 105 (18.8%) 109 (19.5%) 109 (19.5%) 97 (17.4%) 64 (11.4%) Rhabdomyosarcoma, NOS 555 130 (23.4%) 65 (11.7%) 51 (9.2%) 89 (16.0%) 30 (14.4%) 86 (15.5%) 54 (9.7%) Liposarcoma Mixed Type 550 22 (4.0%) 72 (13.1%) 113 (0.5%) 89 (16.0%) 30 (14.4%) 86 (15.5%) 48 (15.5%)	Epithelioid sarcoma	1155	241 (20.9%)	198 (17.1%)	207 (17.9%)	195 (16.9%)	124 (10.7%)	115 (10%)	75 (6.5%)
Hemangiopericytoma, malignant 566 27 (4.8%) 70 (12.4%) 100 (17.7%) 132 (23.3%) 112 (19.8%) 88 (15.5%) 37 (6.59 Pleomorphic rhabdomyosarcoma, adult type 566 24 (4.2%) 38 (6.7%) 69 (12.2%) 102 (18%) 134 (23.7%) 111 (19.6%) 88 (15.5%) 58 (15.5%) 59 (24.4%) 38 (6.7%) 69 (12.2%) 102 (18%) 134 (23.7%) 111 (19.6%) 88 (15.5%) 59 (24.4%) 59 (25.2%) 59 (24.5%)	Chondrosarcoma Myxoid	854	34 (4.0%)	93 (10.9%)	165 (19.3%)	200 (23.4%)	186 (21.8%)	114 (13.3%)	62 (7.3%)
Pleomorphic rhabdomyosarcoma, adult type 566 24 (4.2%) 38 (6.7%) 69 (12.2%) 102 (18%) 134 (23.7%) 111 (19.6%) 88 (15.5%) 05 (20.	Chondrosarcoma, NOS	581	41 (7.1%)	70 (12.0%)	82 (14.1%)	121 (20.8%)	108 (18.6%)	113 (19.4%)	46 (7.9%)
Osteosarcoma, NOS; Chondroblastic osteosarcoma 562	Hemangiopericytoma, malignant	566	27 (4.8%)	70 (12.4%)	100 (17.7%)	132 (23.3%)	112 (19.8%)	88 (15.5%)	37 (6.5%)
osteosarcoma; Fibroblastic osteosarcoma 562 49 (8.7%) 42 (7.5%) 75 (13.3%) 122 (21.7%) 112 (19.9%) 98 (17.4%) 64 (11.49) Myxosarcoma 558 14 (2.5%) 36 (6.5%) 88 (15.8%) 105 (18.8%) 109 (19.5%) 109 (19.5%) 97 (17.4%) Rhabdomyosarcoma, NOS 555 130 (23.4%) 65 (11.7%) 51 (9.2%) 89 (16.0%) 80 (14.4%) 86 (15.5%) 54 (9.7%) Liposarcoma Mixed Type 550 22 (4.0%) 72 (13.1%) 113 (20.5%) 120 (21.8%) 99 (18.0%) 79 (14.4%) 45 (8.2%) Clear cell sarcoma, NOS (except of kidney) 542 116 (21.4%) 111 (20.5%) 105 (19.4%) 89 (16.4%) 51 (9.4%) 44 (8.1%) 26 (4.8%) Liposarcoma Round cell 460 29 (6.3%) 94 (20.4%) 126 (27.4%) 92 (20.0%) 59 (12.8%) 42 (9.1%) 18 (3.9%) Rhabdomyosarcoma Alveolar 384 226 (58.9%) 52 (13.5%) 40 (10.4%) 26 (6.8%) 17 (4.4%) 16 (4.2%) 7 (1.8%) Small cell sarcoma 310 78 (25.2%) </td <td>Pleomorphic rhabdomyosarcoma, adult type</td> <td>566</td> <td>24 (4.2%)</td> <td>38 (6.7%)</td> <td>69 (12.2%)</td> <td>102 (18%)</td> <td>134 (23.7%)</td> <td>111 (19.6%)</td> <td>88 (15.5%)</td>	Pleomorphic rhabdomyosarcoma, adult type	566	24 (4.2%)	38 (6.7%)	69 (12.2%)	102 (18%)	134 (23.7%)	111 (19.6%)	88 (15.5%)
Rhabdomyosarcoma, NOS 555 130 (23.4%) 65 (11.7%) 51 (9.2%) 89 (16.0%) 80 (14.4%) 86 (15.5%) 54 (9.7%) Liposarcoma Mixed Type 550 22 (4.0%) 72 (13.1%) 113 (20.5%) 120 (21.8%) 99 (18.0%) 79 (14.4%) 45 (8.2%) Clear cell sarcoma, NOS (except of kidney) 542 116 (21.4%) 111 (20.5%) 105 (19.4%) 89 (16.4%) 51 (9.4%) 44 (8.1%) 26 (4.8%) Liposarcoma Round cell 460 29 (6.3%) 94 (20.4%) 126 (27.4%) 92 (20.0%) 59 (12.8%) 42 (9.1%) 18 (3.9%) Rhabdomyosarcoma Alveolar 384 226 (58.9%) 52 (13.5%) 40 (10.4%) 26 (6.8%) 17 (4.4%) 16 (4.2%) 7 (1.8%) Alveolar soft part sarcoma 340 209 (61.5%) 69 (20.3%) 30 (8.8%) 20 (5.9%) 6 (1.8%) 6 (1.8%) 15 (4.5%) Small cell sarcoma 310 78 (25.2%) 50 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 18 (5.2%) 34 (11.19) Solitary fibrous tumor, malignant 305 12 (3.9%) </td <td></td> <td>562</td> <td>49 (8.7%)</td> <td>42 (7.5%)</td> <td>75 (13.3%)</td> <td>122 (21.7%)</td> <td>112 (19.9%)</td> <td>98 (17.4%)</td> <td>64 (11.4%)</td>		562	49 (8.7%)	42 (7.5%)	75 (13.3%)	122 (21.7%)	112 (19.9%)	98 (17.4%)	64 (11.4%)
Liposarcoma Mixed Type 550 22 (4.0%) 72 (13.1%) 113 (20.5%) 120 (21.8%) 99 (18.0%) 79 (14.4%) 45 (8.29 (1.28 (1.24	Myxosarcoma	558	14 (2.5%)	36 (6.5%)	88 (15.8%)	105 (18.8%)	109 (19.5%)	109 (19.5%)	97 (17.4%)
Clear cell sarcoma, NOS (except of kidney) 542 116 (21.4%) 111 (20.5%) 105 (19.4%) 89 (16.4%) 51 (9.4%) 44 (8.1%) 26 (4.8%) Liposarcoma Round cell 460 29 (6.3%) 94 (20.4%) 126 (27.4%) 92 (20.0%) 59 (12.8%) 42 (9.1%) 18 (3.9%) Rhabdomyosarcoma Alveolar 384 226 (58.9%) 52 (13.5%) 40 (10.4%) 26 (6.8%) 17 (4.4%) 16 (4.2%) 7 (1.8%) Alveolar soft part sarcoma 340 209 (61.5%) 69 (20.3%) 30 (8.8%) 20 (5.9%) 6 (1.8%) 6 (1.8%) 6 (1.8%) 15 (4.5%) Small cell sarcoma 310 78 (25.2%) 50 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 18 (5.8%) 16 (5.2%) Solitary fibrous tumor, malignant 305 12 (3.9%) 19 (6.2%) 39 (12.8%) 64 (21.0%) 68 (22.3%) 69 (22.6%) 34 (11.19) Desmoplastic small round cell tumor 296 169 (57.1%) 72 (24.3%) 36 (12.2%) 9 (3.0%) 4 (1.4%) 5 (1.7%) 1 (0.3%) Rhabdomyosarcoma Embryonal 277 107 (38.6%) 44 (15.9%) 40 (14.4%) 31 (11.2%) 28 (10.1%) 14 (5.1%) 13 (4.7%) Epithelioid hemangioendothelioma, malignant 213 23 (10.8%) 35 (16.4%) 35 (24.9%) 43 (20.2%) 28 (13.1%) 26 (12.2%) 5 (2.3%) Mesenchymal chondrosarcoma 134 36 (26.9%) 33 (24.6%) 20 (18.5%) 20 (18.5%) 18 (16.7%) 10 (9.3%) 11 (10.2%) 12 (11.19) Mesenchymoma, malignant 90 15 (16.7%) 10 (11.1%) 14 (15.6%) 15 (16.7%) 10 (11.1%) 18 (22.8%) 22 (27.8%)	Rhabdomyosarcoma, NOS	555	130 (23.4%)	65 (11.7%)	51 (9.2%)	89 (16.0%)	80 (14.4%)	86 (15.5%)	54 (9.7%)
Liposarcoma Round cell 460 29 (6.3%) 94 (20.4%) 126 (27.4%) 92 (20.0%) 59 (12.8%) 42 (9.1%) 18 (3.9%) Rhabdomyosarcoma Alveolar 384 226 (58.9%) 52 (13.5%) 40 (10.4%) 26 (6.8%) 17 (4.4%) 16 (4.2%) 7 (1.8%) Alveolar soft part sarcoma 340 209 (61.5%) 69 (20.3%) 30 (8.8%) 20 (5.9%) 6 (1.8%) 6 (1.8%) 15 (4.5%) Small cell sarcoma 310 78 (25.2%) 50 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 18 (5.8%) 16 (5.2%) Solitary fibrous tumor, malignant 305 12 (3.9%) 19 (6.2%) 39 (12.8%) 64 (21.0%) 68 (22.3%) 69 (22.6%) 34 (11.1%) Desmoplastic small round cell tumor 296 169 (57.1%) 72 (24.3%) 36 (12.2%) 9 (3.0%) 4 (1.4%) 5 (1.7%) 1 (0.3%) Rhabdomyosarcoma Embryonal 277 107 (38.6%) 44 (15.9%) 40 (14.4%) 31 (11.2%) 28 (10.1%) 14 (5.1%) 13 (4.7%) Epithelioid hemangioendothelioma, malignant 213 23 (10.8%) 35 (16.4%) 53 (24.9%) 43 (20.2%) 28 (13.1%) 26 (12.2%) 5 (2.3%) Mesenchymal chondrosarcoma 134 36 (26.9%) 33 (24.6%) 20 (14.9%) 16 (11.9%) 12 (9.0%) 11 (8.2%) 6 (4.5%) Malignant myoepithelioma 108 17 (15.7%) 20 (18.5%) 20 (18.5%) 18 (16.7%) 10 (9.3%) 11 (10.2%) 12 (11.1%) Mesenchymoma, malignant 79 0 (0.0%) 1 (1.3%) 9 (11.4%) 10 (12.7%) 19 (24.1%) 18 (22.8%) 22 (27.88)	Liposarcoma Mixed Type	550	22 (4.0%)	72 (13.1%)	113 (20.5%)	120 (21.8%)	99 (18.0%)	79 (14.4%)	45 (8.2%)
Rhabdomyosarcoma Alveolar 384 226 (58.9%) 52 (13.5%) 40 (10.4%) 26 (6.8%) 17 (4.4%) 16 (4.2%) 7 (1.8%) Alveolar soft part sarcoma 340 209 (61.5%) 69 (20.3%) 30 (8.8%) 20 (5.9%) 6 (1.8%) 6 (1.8%) 15 (4.5%) 5 (4.5%) 5 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 18 (5.8%) 16 (5.2%) 50 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 18 (5.8%) 16 (5.2%) 50 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 18 (5.8%) 16 (5.2%) 50 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 18 (5.8%) 16 (5.2%) 50 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 18 (5.8%) 16 (5.2%) 50 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 68 (22.3%) 69 (22.6%) 34 (11.1%) 19 (11.1%) 19 (11.1%) 18 (11.1%) 18 (11.1%) 18 (11.1%) 18 (11.1%) 18 (11.1%) 19 (11	Clear cell sarcoma, NOS (except of kidney)	542	116 (21.4%)	111 (20.5%)	105 (19.4%)	89 (16.4%)	51 (9.4%)	44 (8.1%)	26 (4.8%)
Alveolar soft part sarcoma 340 209 (61.5%) 69 (20.3%) 30 (8.8%) 20 (5.9%) 6 (1.8%) 6 (1.8%) 15 (4.5%) Small cell sarcoma 310 78 (25.2%) 50 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 18 (5.8%) 16 (5.2%) Solitary fibrous tumor, malignant 305 12 (3.9%) 19 (6.2%) 39 (12.8%) 64 (21.0%) 68 (22.3%) 69 (22.6%) 34 (11.1%) Desmoplastic small round cell tumor 296 169 (57.1%) 72 (24.3%) 36 (12.2%) 9 (3.0%) 4 (1.4%) 5 (1.7%) 1 (0.3%) Rhabdomyosarcoma Embryonal 277 107 (38.6%) 44 (15.9%) 40 (14.4%) 31 (11.2%) 28 (10.1%) 14 (5.1%) 13 (4.7%) Epithelioid hemangioendothelioma, malignant 213 23 (10.8%) 35 (16.4%) 53 (24.9%) 43 (20.2%) 28 (13.1%) 26 (12.2%) 5 (2.3%) Mesenchymal chondrosarcoma 134 36 (26.9%) 33 (24.6%) 20 (14.9%) 16 (11.9%) 12 (9.0%) 11 (8.2%) 6 (4.5%) Malignant myoepithelioma 108 17 (15.7%) 20 (18.5%) 20 (18.5%) 18 (16.7%) 10 (9.3%) 11 (10.2%) 12 (11.1%) Mesenchymoma, malignant 90 15 (16.7%) 10 (11.1%) 14 (15.6%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 11 (12.2%) Merkel cell carcinoma 79 0 (0.0%) 1 (1.3%) 9 (11.4%) 10 (12.7%) 19 (24.1%) 18 (22.8%) 22 (27.8%)	Liposarcoma Round cell	460	29 (6.3%)	94 (20.4%)	126 (27.4%)	92 (20.0%)	59 (12.8%)	42 (9.1%)	18 (3.9%)
Small cell sarcoma 310 78 (25.2%) 50 (16.1%) 57 (18.4%) 60 (19.4%) 31 (10.0%) 18 (5.8%) 16 (5.2%) Solitary fibrous tumor, malignant 305 12 (3.9%) 19 (6.2%) 39 (12.8%) 64 (21.0%) 68 (22.3%) 69 (22.6%) 34 (11.19) Desmoplastic small round cell tumor 296 169 (57.1%) 72 (24.3%) 36 (12.2%) 9 (3.0%) 4 (1.4%) 5 (1.7%) 1 (0.39) Rhabdomyosarcoma Embryonal 277 107 (38.6%) 44 (15.9%) 40 (14.4%) 31 (11.2%) 28 (10.1%) 14 (5.1%) 13 (4.7%) Epithelioid hemangioendothelioma, malignant 213 23 (10.8%) 35 (16.4%) 53 (24.9%) 43 (20.2%) 28 (13.1%) 26 (12.2%) 5 (2.3%) Mesenchymal chondrosarcoma 134 36 (26.9%) 33 (24.6%) 20 (14.9%) 16 (11.9%) 12 (9.0%) 11 (8.2%) 6 (4.5%) Malignant myoepithelioma 108 17 (15.7%) 20 (18.5%) 20 (18.5%) 18 (16.7%) 10 (11.1%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 10 (11.1%) 15 (16.7%)	Rhabdomyosarcoma Alveolar	384	226 (58.9%)	52 (13.5%)	40 (10.4%)	26 (6.8%)	17 (4.4%)	16 (4.2%)	7 (1.8%)
Solitary fibrous tumor, malignant 305 12 (3.9%) 19 (6.2%) 39 (12.8%) 64 (21.0%) 68 (22.3%) 69 (22.6%) 34 (11.19) Desmoplastic small round cell tumor 296 169 (57.1%) 72 (24.3%) 36 (12.2%) 9 (3.0%) 4 (1.4%) 5 (1.7%) 1 (0.39) Rhabdomyosarcoma Embryonal 277 107 (38.6%) 44 (15.9%) 40 (14.4%) 31 (11.2%) 28 (10.1%) 14 (5.1%) 13 (4.7%) Epithelioid hemangioendothelioma, malignant 213 23 (10.8%) 35 (16.4%) 53 (24.9%) 43 (20.2%) 28 (13.1%) 26 (12.2%) 5 (2.3%) Mesenchymal chondrosarcoma 134 36 (26.9%) 33 (24.6%) 20 (14.9%) 16 (11.9%) 12 (9.0%) 11 (8.2%) 6 (4.5%) Malignant myoepithelioma 108 17 (15.7%) 20 (18.5%) 20 (18.5%) 18 (16.7%) 10 (9.3%) 11 (10.2%) 12 (11.19) Mesenchymoma, malignant 90 15 (16.7%) 10 (11.1%) 14 (15.6%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 10 (11.1%) 18 (22.8%) 22 (27.8%)	-	340	209 (61.5%)	69 (20.3%)				6 (1.8%)	15 (4.5%)
Desmoplastic small round cell tumor 296 169 (57.1%) 72 (24.3%) 36 (12.2%) 9 (3.0%) 4 (1.4%) 5 (1.7%) 1 (0.39) Rhabdomyosarcoma Embryonal 277 107 (38.6%) 44 (15.9%) 40 (14.4%) 31 (11.2%) 28 (10.1%) 14 (5.1%) 13 (4.79) Epithelioid hemangioendothelioma, malignant 213 23 (10.8%) 35 (16.4%) 53 (24.9%) 43 (20.2%) 28 (13.1%) 26 (12.2%) 5 (2.39) Mesenchymal chondrosarcoma 134 36 (26.9%) 33 (24.6%) 20 (14.9%) 16 (11.9%) 12 (9.0%) 11 (8.2%) 6 (4.5%) Malignant myoepithelioma 108 17 (15.7%) 20 (18.5%) 20 (18.5%) 18 (16.7%) 10 (9.3%) 11 (10.2%) 12 (11.1%) Mesenchymoma, malignant 90 15 (16.7%) 10 (11.1%) 14 (15.6%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 10 (11.2%) 18 (22.8%) 22 (27.8%)					` ,	` ,	,		16 (5.2%)
Rhabdomyosarcoma Embryonal 277 107 (38.6%) 44 (15.9%) 40 (14.4%) 31 (11.2%) 28 (10.1%) 14 (5.1%) 13 (4.79) Epithelioid hemangioendothelioma, malignant 213 23 (10.8%) 35 (16.4%) 53 (24.9%) 43 (20.2%) 28 (13.1%) 26 (12.2%) 5 (2.3%) Mesenchymal chondrosarcoma 134 36 (26.9%) 33 (24.6%) 20 (14.9%) 16 (11.9%) 12 (9.0%) 11 (8.2%) 6 (4.5%) Malignant myoepithelioma 108 17 (15.7%) 20 (18.5%) 20 (18.5%) 18 (16.7%) 10 (9.3%) 11 (10.2%) 12 (11.1%) Mesenchymoma, malignant 90 15 (16.7%) 10 (11.1%) 14 (15.6%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 10 (11.1%) 18 (22.8%) 22 (27.8%)	-								34 (11.1%)
Epithelioid hemangioendothelioma, malignant 213 23 (10.8%) 35 (16.4%) 53 (24.9%) 43 (20.2%) 28 (13.1%) 26 (12.2%) 5 (2.3%) Mesenchymal chondrosarcoma 134 36 (26.9%) 33 (24.6%) 20 (14.9%) 16 (11.9%) 12 (9.0%) 11 (8.2%) 6 (4.5%) Malignant myoepithelioma 108 17 (15.7%) 20 (18.5%) 20 (18.5%) 18 (16.7%) 10 (9.3%) 11 (10.2%) 12 (11.1%) Mesenchymoma, malignant 90 15 (16.7%) 10 (11.1%) 14 (15.6%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 10 (11.1%) 18 (22.8%) 22 (27.8%) Merkel cell carcinoma 79 0 (0.0%) 1 (1.3%) 9 (11.4%) 10 (12.7%) 19 (24.1%) 18 (22.8%) 22 (27.8%)	•				, ,				1 (0.3%)
Mesenchymal chondrosarcoma 134 36 (26.9%) 33 (24.6%) 20 (14.9%) 16 (11.9%) 12 (9.0%) 11 (8.2%) 6 (4.5%) Malignant myoepithelioma 108 17 (15.7%) 20 (18.5%) 20 (18.5%) 18 (16.7%) 10 (9.3%) 11 (10.2%) 12 (11.1%) Mesenchymoma, malignant 90 15 (16.7%) 10 (11.1%) 14 (15.6%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 11 (12.2%) Merkel cell carcinoma 79 0 (0.0%) 1 (1.3%) 9 (11.4%) 10 (12.7%) 19 (24.1%) 18 (22.8%) 22 (27.8%)									
Malignant myoepithelioma 108 17 (15.7%) 20 (18.5%) 20 (18.5%) 18 (16.7%) 10 (9.3%) 11 (10.2%) 12 (11.19) Mesenchymoma, malignant 90 15 (16.7%) 10 (11.1%) 14 (15.6%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 11 (12.29) Merkel cell carcinoma 79 0 (0.0%) 1 (1.3%) 9 (11.4%) 10 (12.7%) 19 (24.1%) 18 (22.8%) 22 (27.89)	, ,								5 (2.3%)
Mesenchymoma, malignant 90 15 (16.7%) 10 (11.1%) 14 (15.6%) 15 (16.7%) 10 (11.1%) 15 (16.7%) 11 (12.29) Merkel cell carcinoma 79 0 (0.0%) 1 (13.3%) 9 (11.4%) 10 (12.7%) 19 (24.1%) 18 (22.8%) 22 (27.8%)	•								6 (4.5%)
Merkel cell carcinoma 79 0 (0.0%) 1 (1.3%) 9 (11.4%) 10 (12.7%) 19 (24.1%) 18 (22.8%) 22 (27.8%)									12 (11.1%)
									11 (12.2%)
Granular cell tumor, malignant /1 8 (11.3%) 9 (12.7%) 14 (19.7%) 18 (25.4%) 15 (21.1%) 5 (7.0%) 2 (2.8%)									
	Granular cell turnor, malignant	/1	δ (11.5%)	9 (12./%)	14 (19.7%)	18 (25.4%)	15 (21.1%)	5 (7.0%)	۷ (۷.۵%)

Source: American College of Surgeons National Cancer Data Base (NCDB).

NOTE: NCDB Adult Soft Tissue Sarcoma Data Summary

Demographic data is available on cases diagnosed from 1998 – 2011. A total of 91,163 cases were available. Mortality is only available from 44,065 cases reported 1998 – 2006. The sample size by cancer type is provided in the tables. The difference in sample size is related to excluding cases without followup data. Per NCDB, mortality data is not available for the last five years of collection (2007-2011). Also, per NCDB, cases were excluded if they had multiple cancer types. Note that this data set only included patients 18 years old and older. Data on children with cancer was not available for this analysis.

The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data used in this study and this report are derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator and authors of this work.